ELVN - NASDAQ
Enliven Therapeutics, Inc.
$37.48
+4.0%Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
At a Glance
Live SnapshotEnliven Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Enliven Therapeutics, Inc. Cash Flow Statement
ELVN • NASDAQ
| Enliven Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||
-103.7M | -89M | -71.6M | -37.7M | -24.7M | -19M | -23.5M | -11.3M | 0.0 | |
263K | 317K | 297K | 215K | 115K | 45K | 33K | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | -3.8M | 0.0 | -215K | 0.0 | 0.0 | |
34M | 20.2M | 12.9M | 3.2M | 1.9M | 130K | 899K | 555K | 0.0 | |
232K | -118K | -4.3M | 1.7M | 3.8M | 9.7M | 196K | 848K | -7.9M | |
(0.0) | (232K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-1.1M | -4.5M | 1.4M | 438K | 3.6M | 583K | 673K | 1.2M | -188K | |
-70.3M | -73.2M | -61.3M | -32.1M | -19.1M | -8.5M | -21.9M | -8.8M | -8.8M | |
INVESTING ACTIVITIES | |||||||||
-158K | -44K | -149K | -612K | -191K | -461K | -140K | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (35M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-446.8M | -350.7M | -268.3M | -35M | -47.6M | -64.2M | -23.9M | (0.0) | (0.0) | |
272.9M | 313.9M | 120M | 41.9M | 45.9M | 47.5M | 0.0 | 0.0 | 0.0 | |
213K | 873K | 0.0 | -41.9M | 1.6M | 16.7M | 0.0 | 0.0 | 0.0 | |
-173.8M | -36M | -148.4M | -612K | -191K | -461K | -24.1M | (0.0) | (0.0) | |
FINANCING ACTIVITIES | |||||||||
218.9M | 39.2M | 161.2M | -1.2M | -1M | 96.9M | 45.6M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2M | 0.0 | 0.0 | |
0.0 | 94M | 73.1M | -566K | 0.0 | 33.6M | 0.0 | 6.5M | 11M | |
218.9M | 133.2M | 234.3M | -1.8M | -1M | 130.5M | 43.6M | 6.5M | 11M | |
CASH FLOW SUMMARY | |||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -88K | 0.0 | 0.0 | |
-25.3M | 24M | 24.6M | -34.5M | -20.3M | 121.5M | -2.4M | -2.3M | 2.2M | |
124.2M | 100.2M | 75.6M | 110.1M | 130.4M | 8.9M | 7.4M | 9.7M | 7.5M | |
98.9M | 124.2M | 100.2M | 75.6M | 110.1M | 130.4M | 4.9M | 7.4M | 9.7M | |
-70.5M | -73.2M | -61.4M | -32.7M | -19.3M | -9M | -22M | -8.8M | -8.8M |
SEC Filings
ELVN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 03, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 07, 2026 | January 06, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 11, 2025 | December 09, 2025 | 2025 | |
8-K/A 8-K/A 2025 (Amended) N/A | November 13, 2025 | November 12, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your ELVN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.